Jae-Hui Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1495642/publications.pdf

Version: 2024-02-01

74	1,039	567144 15	501076 28
papers	citations	h-index	g-index

75	75	75	810
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Risk Factors for Geographic Atrophy After Intravitreal Ranibizumab Injections for Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 2015, 159, 285-292.e1.	1.7	91
2	Assessment of retinal layers and visual rehabilitation after epiretinal membrane removal. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1055-1064.	1.0	90
3	Thinner Choroid and Greater Drusen Extent in Retinal Angiomatous Proliferation Than in Typical Exudative Age-Related Macular Degeneration. American Journal of Ophthalmology, 2013, 155, 743-749.e2.	1.7	77
4	Intravitreal Anti-Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization. Ophthalmology, 2014, 121, 926-935.	2.5	69
5	Asymmetric Elongation of Foveal Tissue after Macular Hole Surgery and Its Impact on Metamorphopsia. Ophthalmology, 2012, 119, 2133-2140.	2.5	51
6	PREVALENCE OF SUBTYPES OF RETICULAR PSEUDODRUSEN IN NEWLY DIAGNOSED EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY IN KOREAN PATIENTS. Retina, 2015, 35, 2604-2612.	1.0	43
7	Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. British Journal of Ophthalmology, 2016, 100, 1634-1639.	2.1	40
8	NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS. Retina, 2017, 37, 2254-2261.	1.0	36
9	Fellowâ€eye neovascularization in unilateral retinal angiomatous proliferation in a <scp>K</scp>orean population. Acta Ophthalmologica, 2016, 94, e49-53.	0.6	32
10	Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 23-30.	1.0	31
11	Choroidal Vascular Hyperpermeability and Punctate Hyperfluorescent Spot in Choroidal Neovascularization. , 2015, 56, 1909.		24
12	Overestimation of subfoveal choroidal thickness by measurement based on horizontally compressed optical coherence tomography images. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1091-1096.	1.0	21
13	DIFFERENCE IN TREATMENT OUTCOMES ACCORDING TO OPTICAL COHERENCE TOMOGRAPHYâ€“BASED STAGES IN TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION). Retina, 2018, 38, 2356-2362.	1.0	18
14	Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment. Scientific Reports, 2019, 9, 13264.	1.6	17
15	Characteristics of Perifoveal Exudative Vascular Anomalous Complex in Korean Patients. Seminars in Ophthalmology, 2019, 34, 353-358.	0.8	17
16	Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 891-898.	1.0	16
17	Topographic Changes of Retinal Layers after Resolution of Acute Retinal Detachment. , 2012, 53, 7316.		15
18	Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1573-1579.	1.0	15

#	Article	IF	Citations
19	DIAGNOSIS OF TYPE 3 NEOVASCULARIZATION BASED ON OPTICAL COHERENCE TOMOGRAPHY IMAGES. Retina, 2016, 36, 1506-1515.	1.0	13
20	Characteristics of Submacular Hemorrhages in Age-Related Macular Degeneration. Optometry and Vision Science, 2017, 94, 556-563.	0.6	13
21	Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 2018, 62, 54-62.	0.9	13
22	Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 107-116.	1.0	13
23	The Effects of Cataract Surgery on Patients With Wet Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 1312.	1.7	12
24	Incidence and Timing of the First Recurrence in Neovascular Age-Related Macular Degeneration: Comparison Between Ranibizumab and Aflibercept. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 445-451.	0.6	12
25	Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema. Acta Ophthalmologica, 2015, 93, e178-e179.	0.6	11
26	RECURRENCE IN PATIENTS WITH TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION) AFTER INTRAVITREAL RANIBIZUMAB. Retina, 2017, 37, 1508-1515.	1.0	11
27	Prechoroidal Cleft in Type 3 Neovascularization: Incidence, Timing, and Its Association with Visual Outcome. Journal of Ophthalmology, 2018, 2018, 1-8.	0.6	11
28	Early Recurrent Hemorrhage in Submacular Hemorrhage Secondary to Type 3 Neovascularization or Retinal Angiomatous Proliferation: Incidence and Influence on Visual Prognosis. Seminars in Ophthalmology, 2018, 33, 820-828.	0.8	11
29	Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients. Journal of Ophthalmology, 2018, 2018, 1-9.	0.6	11
30	Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization. Seminars in Ophthalmology, 2020, 35, 33-40.	0.8	11
31	Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring. Journal of Clinical Medicine, 2020, 9, 1145.	1.0	11
32	Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis. BMJ Open, 2020, 10, e042484.	0.8	10
33	Imaging Suprachoroidal Layer in Exudative Age-Related Macular Degeneration. Current Eye Research, 2016, 41, 715-720.	0.7	9
34	Hyperpigmented spots after treatment for submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 469-477.	1.0	9
35	Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting. Korean Journal of Ophthalmology: KJO, 2018, 32, 361.	0.5	9
36	Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1661-1669.	1.0	9

#	Article	IF	Citations
37	Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1183-1189.	1.0	9
38	Fibrovascular pigment epithelial detachment in eyes with subretinal hemorrhage secondary to neovascular AMD or PCV: a morphologic predictor associated with poor treatment outcomes. Scientific Reports, 2020, 10, 14943.	1.6	9
39	Long-term Clinical Course after Vitrectomy for Breakthrough Vitreous Hemorrhage Secondary to Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Scientific Reports, 2020, 10, 359.	1.6	9
40	Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1821-1830.	1.0	9
41	Vitrectomy Combined with Intravitreal Triamcinolone Acetonide Injection and Macular Laser Photocoagulation for Nontractional Diabetic Macular Edema. Korean Journal of Ophthalmology: KJO, 2013, 27, 186.	0.5	8
42	LONG-TERM VISUAL CHANGES IN INITIALLY STRONGER FELLOW EYES IN PATIENTS WITH UNILATERAL TYPE 3 NEOVASCULARIZATION. Retina, 2019, 39, 1672-1681.	1.0	8
43	Radiating hemorrhage in exudative age-related macular degeneration. Japanese Journal of Ophthalmology, 2016, 60, 466-475.	0.9	7
44	Long-term natural history of the idiopathic epiretinal membrane in children and young adults. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2141-2150.	1.0	7
45	Polypoidal choroidal vasculopathy in patients aged less than 50Âyears: characteristics and 6-month treatment outcome. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1083-1089.	1.0	6
46	Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization. International Journal of Ophthalmology, 2019, 12, 480-487.	0.5	6
47	A conjunctival cyst with delayed internal hemorrhage after strabismus surgery. Journal of AAPOS, 2008, 12, 409-411.	0.2	5
48	Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 207.	1.7	5
49	Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections. Seminars in Ophthalmology, 2018, 33, 371-376.	0.8	5
50	Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1677-1685.	1.0	5
51	Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome. Korean Journal of Ophthalmology: KJO, 2017, 31, 240.	0.5	4
52	Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Journal of Clinical Medicine, 2021, 10, 3580.	1.0	4
53	Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 525-533.	0.6	4
54	Long-term Changes in Choroidal Thickness in Eyes with Type 3 Macular Neovascularization. Retina, 2020, Publish Ahead of Print, 1251-1258.	1.0	4

#	Article	IF	Citations
55	Efficacy of Intravitreal Bevacizumab for Recurrent Central Serous Chorioretinopathy in Patients Who Had Previously Responded Well to the Same Therapy. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 425-430.	0.6	3
56	Influence of bevacizumab therapy and intraretinal hemorrhage in long-term outcomes of hemorrhagic retinal arterial macroaneurysm. Scientific Reports, 2021, 11, 14246.	1.6	3
57	Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy. Journal of Clinical Medicine, 2021, 10, 5739.	1.0	3
58	The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Threshold Test. Journal of Glaucoma, 2010, 19, 257-263.	0.8	2
59	Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion. Journal of Ophthalmology, 2021, 2021, 1-8.	0.6	2
60	LONG-TERM COURSE AND VISUAL OUTCOMES OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2021, 41, 2436-2445.	1.0	2
61	Characteristics of spontaneous reattachment of rhegmatogenous retinal detachment: optical coherence tomography features and follow-up outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3703-3710.	1.0	2
62	Clinical Evaluation of Accommodative Intraocular Lens Implantation in High Myopic Eyes. Korean Journal of Ophthalmology: KJO, 2008, 22, 81.	0.5	1
63	Polypoidal Choroidal Vasculopathy with Feeder Vessels: Characteristics, Fellow Eye Findings, and Long-term Treatment Outcomes. Korean Journal of Ophthalmology: KJO, 2017, 31, 230.	0.5	1
64	Visual Prognosis in the Better-seeing Eyes of Patients with Unilateral Polypoidal Choroidal Vasculopathy. Optometry and Vision Science, 2019, 96, 686-694.	0.6	1
65	Decreased Periodicity of Reactivation Interval in Neovascular Age-Related Macular Degeneration in Patients with a Late First Reactivation After Initial Treatment. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 703-710.	0.6	1
66	Proportion of and Reason for Bevacizumab Usage in the Treatment of Wet Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2021, 62, 1076-1083.	0.0	1
67	Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation: A Review of the Literature and Therapeutic Considerations. Journal of Retina, 2016, 1, 11-22.	0.1	1
68	Re: Yamamoto etÂal.: One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy (Ophthalmology 2015;122:1866-72). Ophthalmology, 2016, 123, e13.	2.5	0
69	Long-Term Outcomes of Switching from Fixed-Dose to As-Needed Regimen for Treating Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy. Journal of Clinical Medicine, 2020, 9, 2637.	1.0	0
70	Re: Nguyen etÂal.: Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents (Ophthalmology.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137 Td		
71	Short-Term Outcomes of Cataract Surgery in Patients with a History of Central Serous Chorioretinopathy. Journal of Ophthalmology, 2021, 2021, 1-6.	0.6	0
72	Proportion and Reasons for Ineligibility to Re-register for Extended Health Insurance in Neovascular Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2021, 62, 948-956.	0.0	0

#	Article	IF	Citations
73	Development of Subretinal Hemorrhage during Treatment of Neovascular Age-related Macular Degeneration Using a Treat-and-extend Regimen: A Case Report. Journal of Retina, 2021, 6, 155-161.	0.1	0
74	Development of subretinal hemorrhage after treatment discontinuation for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , .	1.0	0